Following the release of its Q4 2025 and full-year 2025 financials, Altria Group regained a Buy rating from analysts who cited enhanced clarity on future earnings and shareholder distributions. The company reported adjusted diluted EPS growth of 4.2% year-over-year and announced a 5% dividend increase, marking the fifth consecutive annual raise. Guidance through 2028 projects compound annual growth of 3% in EPS and a 4% annualized dividend hike, reinforcing expectations of stable income for medium-term investors.

Recent share price volatility has driven Altria’s dividend yield to approximately 6.8%, the highest level in seven years, offering a compelling income stream relative to consumer-staples peers. With a forward P/E near its three-year trough and free cash flow conversion above 90% of net income, the valuation discount appears warranted by near-term uncertainties but leaves room for multiple expansion should volume trends stabilize or alternative-product revenues accelerate.

In January 2026, the U.S. Food and Drug Administration granted marketing authorization for Altria’s nicotine-pouch brand, a milestone expected to underpin incremental revenue beginning in H2 2026. Company forecasts estimate nicotine-pouch net revenue reaching $350 million by 2027, translating to roughly 2% of total segment sales. This new product category could contribute 50 basis points of margin expansion by 2028, assuming successful national distribution and consumer trial rates above 20%.

The traditional smokeable segment, still representing 87.5% of consolidated net revenue in Q4 2025, continues to experience secular volume declines. Industry volumes fell an estimated 5% annually last year, driven by reduced price elasticity and shifting consumer demand toward discount offerings. Altria reported a 3.8% drop in unit shipments and a 1.2% decline in Marlboro market share, underscoring the challenge of sustaining pricing power without accelerating down-trading.